Journal of Neurology and Neurorehabilitation Research

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Perspective - Journal of Neurology and Neurorehabilitation Research (2023) Volume 8, Issue 6

Understanding ependymoma: Current insights and therapeutic advances

Kenzo Takenaka*

Department of Neurohistology, University of Yamanashi, Yamanashi, Japan

*Corresponding Author:
Kenzo Takenaka
Department of Neurohistology,
University of Yamanashi,
Yamanashi,
Japan
E-mail: takeken@mail.doshisha.ac.jp

Received: 20-Nov-2023, Manuscript No. JNNR-23-120555; Editor assigned: 21-Nov-2023, JNNR-23-120555 (PQ); Reviewed: 05-Dec-2023, QC No. JNNR-23-120555; Revised: 20-Jan-2024, Manuscript No. JNNR-23-120555 (R); Published: 27-Jan-2024, DOI: 10.35841/aajnnr-9.1.190

Citation: Takenaka K. Understanding ependymoma: Current insights and therapeutic advances. J Neurol Neurorehab Res. 2024;9(1):190.

Introduction

Ependymoma, a rare form of primary brain or spinal cord tumor, arises from the ependymal cells lining the ventricles of the brain and the central canal of the spinal cord. Though infrequent compared to other brain tumors, its impact can be substantial due to its complexities and the challenges in its treatment.

Epidemiology: Ependymomas represent a small percentage of brain tumors, accounting for around 2-3% of all primary brain tumors in both pediatric and adult populations. They can occur at any age but are more frequently diagnosed in children [1].

Description

Etiology and risk factors

The exact cause of ependymoma remains elusive, with no clearly defined risk factors. However, some genetic predispositions or syndromes might increase susceptibility to developing this tumor. These include Neurofibromatosis Type 2 (NF2) and Li-Fraumeni syndrome, among others [2].

Classification

Ependymomas are categorized based on their location within the Central Nervous System (CNS) and histological characteristics. Classification involves various grades: Grade I (subependymoma), grade II (classic ependymoma), and grade III (anaplastic ependymoma), with varying prognoses and treatment approaches.

Pathophysiology and molecular markers: Explore the underlying biology of ependymomas, focusing on molecular markers, genetic mutations, and signalling pathways implicated in tumor development [3].

Clinical presentation

Symptoms of ependymomas can vary widely based on their location within the CNS. Common signs include headaches, nausea, vomiting, seizures, and neurological deficits such as weakness or sensory changes. Diagnosis typically involves imaging studies like MRI or CT scans, followed by histological analysis through biopsy [4].

Treatment modalities

• Surgery: Discuss the role of surgery as the primary treatment and the challenges associated with complete resection.
• Radiation therapy: Explore the use of radiation in treating ependymomas, including its efficacy and potential side effects.
• Chemotherapy: Assess the role of chemotherapy in managing ependymomas, including its limitations and emerging approaches.

Challenges in management

The management of ependymoma presents several challenges. Due to its location in critical areas of the CNS and potential for infiltrative growth, complete surgical removal might be difficult. Furthermore, the blood-brain barrier limits the effectiveness of certain chemotherapy agents [5].

Emerging therapies and research

Recent advancements in molecular profiling and understanding tumor biology have opened avenues for targeted therapies. Immunotherapy and novel drug delivery systems are being explored to improve treatment efficacy while minimizing adverse effects. Clinical trials focusing on personalized medicine approaches are underway, offering hope for more tailored treatments.

Prognosis and long-term considerations

Prognosis varies significantly depending on factors such as tumor grade, extent of resection, and age at diagnosis. Longterm monitoring is essential due to the potential for tumor recurrence, necessitating regular imaging and clinical followups to detect any signs of recurrence or treatment-related complications.

Conclusion

Ependymomas pose significant challenges in diagnosis and management due to their rarity and complexity. While progress in understanding its molecular underpinnings and advancements in treatment strategies offers hope, continued research and collaborative efforts are crucial in improving outcomes and quality of life for individuals affected by this condition. Advances in molecular profiling and targeted therapies offer promising avenues for improved management and prognosis. Multidisciplinary approaches involving surgery, radiation, and evolving systemic therapies are crucial in addressing this condition effectively.

References

Get the App